FY2025 EPS Estimates for Prothena Reduced by HC Wainwright

Key Points

• HC Wainwright has significantly lowered Prothena's FY2025 earnings per share (EPS) estimate from ($2.78) to ($4.13), maintaining a "Buy" rating with a target price of $14.00.
• Prothena's recent earnings report showed a miss, with EPS of ($1.86) compared to the expected ($1.11).
• Currently, there is a consensus rating of "Hold" for Prothena with a price target averaging $30.25, despite mixed analyst opinions.

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Prothena in a note issued to investors on Tuesday, August 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of ($4.13) per share for the year, down from their previous forecast of ($2.78). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena's FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($5.22) EPS, FY2028 earnings at ($2.49) EPS and FY2029 earnings at ($3.34) EPS.

Other equities analysts have also recently issued reports about the company. Bank of America reissued an "underperform" rating on shares of Prothena in a report on Wednesday, May 28th. Chardan Capital reissued a "buy" rating and issued a $18.00 target price on shares of Prothena in a research report on Tuesday. Oppenheimer lowered shares of Prothena from an "outperform" rating to a "market perform" rating in a research report on Tuesday, May 27th. JMP Securities cut their target price on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research report on Tuesday, May 27th. Finally, Jefferies Financial Group downgraded shares of Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target on the stock. in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Prothena presently has a consensus rating of "Hold" and a consensus price target of $30.25.

Prothena Stock Up 12.7%

Shares of Prothena stock opened at $7.92 on Thursday. Prothena has a twelve month low of $4.32 and a twelve month high of $23.66. The company's 50 day moving average is $6.07 and its 200 day moving average is $9.76. The company has a market cap of $426.33 million, a price-to-earnings ratio of -1.40 and a beta of -0.03.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.75). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The company had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million.

Institutional Trading of Prothena

A number of hedge funds and other institutional investors have recently modified their holdings of PRTA. Prospera Financial Services Inc bought a new position in Prothena in the 2nd quarter worth $61,000. Virtus ETF Advisers LLC boosted its stake in Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 833 shares during the period. GAMMA Investing LLC grew its holdings in Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock valued at $74,000 after buying an additional 5,875 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Prothena during the second quarter valued at approximately $85,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Prothena during the second quarter worth $101,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.